Perfil
Gilbert Wagener is currently the Chief Medical Officer at Pharnext SA since 2023.
Prior to this, he held the same position at Cell2B - Advanced Therapeutics SA and Ixaka Ltd. Dr. Wagener holds a doctorate from Erasmus University Rotterdam and Philipps University of Marburg, and an MBA from the University of Basel.
Cargos activos de Gilbert Wagener
| Empresas | Cargo | Inicio |
|---|---|---|
| PHARNEXT SCA | Director Técnico/Científico/I+D | 15/06/2023 |
Antiguos cargos conocidos de Gilbert Wagener.
| Empresas | Cargo | Fin |
|---|---|---|
Ixaka Ltd.
Ixaka Ltd. BiotechnologyHealth Technology Operates as a preclinical-stage immunotherapy biotech company | Director Técnico/Científico/I+D | - |
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Develops stem cell therapies and pharmaceuticals | Director Técnico/Científico/I+D | - |
Formación de Gilbert Wagener.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Erasmus University Rotterdam
Erasmus University Rotterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Basel
University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Philipps University of Marburg
Philipps University of Marburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharnext SA
Pharnext SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for patients to treat neurodegenerative diseases | Health Technology |
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Develops stem cell therapies and pharmaceuticals | Health Technology |
Ixaka Ltd.
Ixaka Ltd. BiotechnologyHealth Technology Operates as a preclinical-stage immunotherapy biotech company | Health Technology |
- Bolsa de valores
- Insiders
- Gilbert Wagener
















